Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Unknown 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

NET 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors Metastatic to the Liver 1Melanoma 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 290Drug Therapy 276Bevacizumab 248apatinib 247camrelizumab 219Etoposide 201Irinotecan 182Doxorubicin 181Leucovorin 163Dexamethasone 161pembrolizumab 153Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Rose Bengal B × Clear all
NCT02557321 2023-11-21

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Provectus Pharmaceuticals

Phase 1/2 Unknown
50 enrolled
Dermatologic

Melanoma

NCT02693067 2023-02-08

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Provectus Pharmaceuticals

Phase 1 Unknown
12 enrolled
EndocrineNET

Neuroendocrine Tumors Metastatic to the Liver

Data powered by HemOnc (CC BY 4.0) Colophon âš¡